Expanded Access Program for Autologous Muscle Derived Cells (AMDCs) (AMDC)

This is an expanded access program (EAP) for eligible participants designed to provide access to autologous muscle derived cells (AMDCs). Treating physicians may submit requests for expanded access to Cook MyoSite's investigational product by email to MYO-ExpandedAccess@CookMyoSite.com.

Study Overview

• Status: Available
• Intervention / Treatment: Biological: Autologous Muscle Derived Cells (AMDCs)

Detailed Description

Cook MyoSite, Inc. (Cook MyoSite) is committed to conducting rigorous, controlled clinical trials with variable inclusion and exclusion criteria based upon the indicated use under investigation. Participation in our clinical trials is the first and most preferable route to access our investigational product.

We understand that there may be patients with a serious, life-threatening disease or condition that have explored all other treatment options and are unable or ineligible to participate in our clinical trials. Expanded access, otherwise known as "compassionate use" or "pre-approval access," is a potential pathway to access an investigational product that a patient may otherwise be unable to receive.

Cook MyoSite will consider providing an investigational product to a qualified requesting physician currently licensed within the United States via the United States Food and Drug Administration's (FDA's) expanded access pathway outside of an active clinical trial when eligibility criteria are met.

• Study Type: Expanded Access
• Expanded Access Type: Individual Patients

Contacts and Locations

• Study Contact: Name: Cook MyoSite; Phone Number: 412-963-7380; Email: MYO-ExpandedAccess@CookMyoSite.com

Study Locations

• United States
  • Pennsylvania
    • Pittsburgh, Pennsylvania, United States, 15238
      • Available
      • Cook Myosite, Inc.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: N/A

Description

Eligibility Criteria:

1. The patient has a serious or life-threatening disease or condition with no satisfactory alternative.
2. Positive assessment that the anticipated benefits outweigh the risks to the patient.
3. Positive assessment that Cook MyoSite has an adequate supply of resources for producing the investigational product.
4. A determination that expanded access will not interfere with Cook MyoSite's ability to complete clinical trials in a timely fashion or which might otherwise delay marketing approval and ultimately availability to all patients.
5. The patient can undergo a muscle biopsy procedure(s).
6. The patient can undergo Cook MyoSite's required donor screening and testing.

Study Plan

How is the study designed?

Collaborators and Investigators

• Sponsor: Cook MyoSite

Publications and helpful links

Helpful Links

• Cook MyoSite, Inc. Expanded Access Webpage
• Cook MyoSite, Inc. Webpage

Study record dates

Study Registration Dates

• First Submitted: December 3, 2020
• First Submitted That Met QC Criteria: December 9, 2020
• First Posted (Actual): December 10, 2020

Study Record Updates

• Last Update Posted (Estimated): February 9, 2024
• Last Update Submitted That Met QC Criteria: February 8, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Other Study ID Numbers: AMDC-EAP